End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.65 CNY | -0.10% | +4.35% | -8.26% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.26% | 122.41Cr | - | ||
-4.67% | 1.23TCr | B+ | ||
-5.19% | 806.62Cr | B- | ||
+9.45% | 591.18Cr | B | ||
+28.50% | 552.21Cr | C | ||
-8.09% | 421.2Cr | C | ||
-55.31% | 299.39Cr | D+ | ||
+13.49% | 273.28Cr | - | - | |
-1.34% | 242.91Cr | B- | ||
+32.24% | 228.89Cr | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688389 Stock
- Ratings Shenzhen Lifotronic Technology Co., Ltd.